Fluciclovine 18F

Drug Profile

Fluciclovine 18F

Alternative Names: 18F-FACBC; 18F fluciclovine; Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic-acid; Anti-1-amino-3-fluorine-18-fluorocyclobutane-1-carboxylic acid; Anti-18-F-FACBC; Anti-3-18F-FACBC; Anti-F-18-fluorocyclobutane-carboxylic-acid; Axumin; FACBC; NMK-36

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Emory University
  • Developer Blue Earth Diagnostics; Emory University; GE Healthcare; Memorial Sloan-Kettering Cancer Center; Nihon Medi-Physics
  • Class Amino acids; Carboxylic acids; Cyclobutanes; Imaging agents; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase III Glioma
  • Clinical Phase Unknown Brain cancer; Head and neck cancer
  • No development reported Breast cancer; Lung cancer; Parathyroid cancer

Most Recent Events

  • 24 Oct 2016 Efficacy and adverse data from a phase III trial in Prostate cancer released by Blue Earth Diagnostics
  • 24 Aug 2016 Nihon Medi-Physics completes a phase II trial for Prostate cancer (Diagnosis) in Japan (IV) (JapicCTI-142707)
  • 16 Jul 2016 No recent reports of development identified for phase-0 development in Breast-cancer(Diagnosis) in USA (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top